<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TACLONEX- calcipotriene and betamethasone dipropionateÂ ointmentÂ </strong><br>Warner Chilcott (US), LLC<br></p></div>
<h1>TACLONEX<span class="Sup">Â®</span><br>(calcipotriene 0.005% and betamethasone dipropionate 0.064%)<br>OINTMENT<br>Â Â </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33aa15fe-2512-443a-9fb4-6403fa4f1349"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">FOR TOPICAL USE ONLY.</span></p>
<p><span class="Bold">Not for Ophthalmic, Oral or Intravaginal Use.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_2f2a3fc9-38d6-4b1d-838c-132402ca2449"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Taclonex<span class="Sup">Â®</span> Ointment contains calcipotriene hydrate and betamethasone dipropionate. <br>It is intended for topical use.</p>
<p>Calcipotriene hydrate is a synthetic vitamin D<span class="Sub">3</span> analogue.</p>
<p>Chemically, calcipotriene hydrate is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1(Î±),3(Î²),24-triol,hydrate, with the empirical formula C<span class="Sub">27</span>H<span class="Sub">40</span>O<span class="Sub">3</span>,H<span class="Sub">2</span>O, a molecular weight of 430.6, and the following structural formula:</p>
<p>Â </p>
<div class="Figure"><img alt="Structural formula of calcipotriene hydrate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-01.jpg"></div>
<p>Calcipotriene hydrate is a white to almost white crystalline compound.</p>
<p>Betamethasone dipropionate is a synthetic corticosteroid.</p>
<p>Betamethasone dipropionate has the chemical name 9-fluoro-11(Î²),17,21-trihydroxy-16(Î²)-methylpregna-1,4-diene-3,20-dione17,21-dipropionate, with the empirical formula C<span class="Sub">28</span>H<span class="Sub">37</span>FO<span class="Sub">7</span>, a molecular weight of 504.6, and the following structural formula:</p>
<div class="Figure"><img alt="Structural formula of Betamethasone dipropionate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-02.jpg"></div>
<p>Betamethasone dipropionate is a white to almost white odorless powder.</p>
<p>Each gram of Taclonex<span class="Sup">Â®</span> Ointment contains 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone) in an ointment base of mineral oil, PPG-15 stearyl ether, dl-alpha tocopherol and white petrolatum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e087e47e-1765-4de3-ad97-f9ac4e80f234"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">Taclonex<span class="Sup">Â®</span> Ointment:</span></p>
<p>Taclonex<span class="Sup">Â®</span> Ointment combines the pharmacological effects of calcipotriene hydrate and betamethasone dipropionate as described below.</p>
<p>In a vasoconstrictor study, the skin <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> response of Taclonex<span class="Sup">Â®</span> Ointment was consistent with that of a potent corticosteroid.</p>
<p><span class="Bold">Calcipotriene</span></p>
<p><span class="Bold">Pharmacokinetics:  </span>Calcipotriene metabolism following systemic uptake is rapid and occurs in the liver. The primary metabolites of calcipotriene are less potent than the parent compound.</p>
<p><span class="Bold">Betamethasone dipropionate</span></p>
<p>Like other topical corticosteroids, betamethasone dipropionate has anti-inflammatory, antipruritic and vasoconstrictive properties. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> vulgaris are uncertain.</p>
<p><span class="Bold">Pharmacokinetics:  </span>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin may increase percutaneous absorption.</p>
<p>There are no human data regarding the distribution of corticosteroids to body organs following topical application. Nevertheless, once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.</p>
<p>Taclonex<span class="Sup">Â®</span> Ointment was applied once daily for 4 weeks to adult patients (N = 12) with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> vulgaris to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis. Of eleven patients tested, none demonstrated adrenal suppression as indicated by a 30-minute post-stimulation cortisol level â‰¤ 18 mcg/dL.</p>
<p>However in another clinical study of Taclonex<span class="Sup">Â®</span> Ointment, one subject (N = 19) demonstrated adrenal suppression.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_971e54a1-db05-4bb2-87d9-5d673e626a3c"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In an international, multi-center, double-blind, vehicle- and active-controlled, parallel-group study, 1,603 patients with mild to very severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> vulgaris on trunk and limbs were treated once daily for 4 weeks. Patients were randomized to one of four treatment arms: Taclonex<span class="Sup">Â®</span> Ointment, calcipotriene hydrate 50 mcg/g in the same vehicle, betamethasone dipropionate 0.64 mg/g in the same vehicle, and vehicle alone. The mean age of the patients was 48.4 years and 60.5% were male. Most patients had disease of moderate severity at baseline.</p>
<p>Efficacy was assessed as the proportion of patients with absent or very mild disease according to the Investigatorâ€™s Global Assessment of Disease Severity at end of treatment (4 weeks). â€œAbsentâ€? disease was defined as no evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, thickness, or scaling. â€œVery mild diseaseâ€? was defined as controlled disease, but not entirely cleared: lesions with some discoloration with absolutely minimal thickness, i.e. the edges to the lesion(s) could just be felt.</p>
<a name="id_f19b5a47-29fa-4432-8616-d3958a1eafe1"></a><table border="single" width="686">
<caption><span>PERCENTAGE OF PATIENTS WITH ABSENT OR VERY MILD DISEASE ACCORDING TO THE INVESTIGATORâ€™S GLOBAL ASSESSMENT OF DISEASE SEVERITY AT END OF TREATMENT (4 WEEKS)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>.</span></caption>
<col width="26.4%">
<col width="20.8%">
<col width="16.8%">
<col width="20.0%">
<col width="16.0%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>PATIENTS WITH MILD DISEASE AT BASELINE WERE REQUIRED TO HAVE â€œABSENTâ€? DISEASE TO BE CONSIDERED A SUCCESS.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Taclonex<span class="Sup">Â® </span>Ointment</p>N = 490</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Calcipotriene</p>N = 480</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Betamethasone dipropionate</p>N = 476</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Vehicle</p>N = 157</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Absent or very mild disease</span></td>
<td class="Rrule" align="center" valign="top">48.0%</td>
<td class="Rrule" align="center" valign="top">16.5%</td>
<td class="Rrule" align="center" valign="top">26.3%</td>
<td class="Botrule Rrule" align="center" valign="top">7.6%</td>
</tr>
</tbody>
</table>
<p>In addition to the pivotal study (N = 490), four randomized, double-blind, vehicle- or active-controlled, parallel-group studies were conducted and provided supportive evidence of efficacy. These studies included a total of 1,058 patients treated with Taclonex<span class="Sup">Â®</span> Ointment once daily for up to 4 weeks.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d8204a39-a9e3-4261-8af3-7f2278d52b04"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Taclonex<span class="Sup">Â®</span> Ointment is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g.Â Treatment of more than 30% body surface area is not recommended. </p>
<p>Taclonex<span class="Sup">Â®</span> Ointment should not be applied to the face, axillae or groin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ddcaadac-f7fc-46c0-a84d-f41ea3f2ab0f"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Taclonex<span class="Sup">Â®</span> Ointment is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.</p>
<p>Taclonex<span class="Sup">Â®</span> Ointment is contraindicated in patients with known or suspected disorders of calcium metabolism.</p>
<p>Taclonex<span class="Sup">Â®</span> Ointment is contraindicated in patients with erythrodermic, exfoliative and <span class="product-label-link" type="condition" conceptid="4063434" conceptname="Pustular psoriasis">pustular psoriasis</span>.Â </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c0485ffa-39fb-4900-943b-7a204fbd92a4"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_8cb3e5f5-8028-4436-9604-8163fa2ae2b3"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> has been observed with use of Taclonex<span class="Sup">Â® </span>Ointment. If elevation of serum calcium outside the normal range occurs, discontinue treatment until normal calcium levels are restored. In the trials that included assessment of the effects of Taclonex<span class="Sup">Â® </span>Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Taclonex<span class="Sup">Â®</span> Ointment on calcium metabolism following treatment durations of longer than 4 weeks are not known.</p>
<p>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushingâ€™s syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. (See <span class="Bold"><a href="#i4i_dosage_admin_id_f042fb6b-401f-4ef1-939d-0cdee847f88f">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the Cosyntropin Stimulation Test. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the topical corticosteroid. </p>
<p>The use of Taclonex<span class="Sup">Â®</span> Ointment has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or severe hepatic disorders.</p>
<p>HPA axis suppression has been observed with Taclonex<span class="Sup">Â® </span>Ointment.</p>
<p>If irritation develops, Taclonex<span class="Sup">Â®</span> Ointment should be discontinued and appropriate therapy instituted.</p>
<p><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> with corticosteroids is usually diagnosed by observing failure to heal rather than by noting any clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.</p>
<p>If concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> are present or develop after treatment initiations, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Taclonex<span class="Sup">Â®</span> Ointment should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
<p>Taclonex<span class="Sup">Â®</span> Ointment should not be used in the presence of pre-existing <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span> at the treatment site. </p>
<p>Taclonex<span class="Sup">Â®</span> Ointment should not be used on the face, axillae or groin.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_fceccf2c-7141-43c9-bdab-52a7ba78a547"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.</p>
<p>Patients using Taclonex<span class="Sup">Â®</span> Ointment should receive the following information and instructions.</p>
<ol>
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the face or eyes. As with any topical medication, patients should wash hands after application.</li>
<li>This medication should not be used for any disorder other than that for which it has been prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive, unless directed by the physician.</li>
<li>Patients should report any signs of adverse reactions to their physician.</li>
<li>Other products containing calcipotriene or a corticosteroid should not be used with Taclonex<span class="Sup">Â®</span> Ointment without first talking to the physician.</li>
<li>Patients who apply Taclonex<span class="Sup">Â®</span> Ointment to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of phototherapy in patients who use Taclonex<span class="Sup">Â®</span> Ointment.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_8d045f8a-81d3-470e-af2b-9eff46f17d08"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">See <span class="Bold"><a href="#i4i_precautions_id_c0485ffa-39fb-4900-943b-7a204fbd92a4">PRECAUTIONS</a></span>, <span class="Bold"><a href="#i4i_precautions_general_id_8cb3e5f5-8028-4436-9604-8163fa2ae2b3">General</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_865fb9b5-0e94-4778-827b-ae325cfa159f"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility:</h2>
<p class="First">When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m<span class="Sup">2</span>/day), no significant changes in tumor incidence were observed when compared to control.</p>
<p>In a study in which albino hairless mice were exposed to both ultra-violet radiation (UVR) and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span>. Patients who apply Taclonex<span class="Sup">Â®</span> Ointment to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of phototherapy in patients that use Taclonex<span class="Sup">Â®</span> Ointment.</p>
<p>Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.</p>
<p>Calcipotriene did not elicit any genotoxic effects in the Ames mutagenicity assay, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK locus assay, the human lymphocyte chromosome aberration test, or the mouse micronucleus test.</p>
<p>Betamethasone dipropionate did not elicit any genotoxic effects in the Ames mutagenicity assay, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK locus assay, or in the rat micronucleus test.</p>
<p>Studies in rats with oral doses of up to 54 mcg/kg/day (324 mcg/m<span class="Sup">2</span>/day) of calcipotriene demonstrated no impairment of fertility or general reproductive performance.</p>
<p>Studies in rats with oral doses of up to 0.2 mg/kg/day (1,200 mcg/m<span class="Sup">2</span>/day) of betamethasone dipropionate demonstrated no impairment of male fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ced2da69-1da7-4a28-bebd-017b7c6589ca"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy:</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_77e71561-424b-4519-9ede-1e09b20432ec"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects: Pregnancy Category C</span></h3>
<p class="First">Animal reproduction studies have not been conducted with Taclonex<span class="Sup">Â®</span> Ointment. Taclonex<span class="Sup">Â®</span> Ointment contains calcipotriene that has been shown to be fetotoxic and betamethasone dipropionate that has been shown to be teratogenic in animals when given systemically. There are no adequate and well-controlled studies in pregnant women. Taclonex<span class="Sup">Â®</span> Ointment should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. </p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with calcipotriene were performed by the oral route in rats and rabbits. In rabbits, increased maternal and fetal toxicity were noted at dosage of 12 mcg/kg/day (144 mcg/m<span class="Sup">2</span>/day); a dosage of 36 mcg/kg/day (432 mcg/m<span class="Sup">2</span>/day) resulted in a significant increase in the incidence of incomplete ossification of the pubic bones and forelimb phalanges of fetuses. In a rat study, a dosage of 54 mcg/kg/day (324 mcg/m<span class="Sup">2</span>/day) resulted in a significantly increased incidence of skeletal abnormalities (enlarged fontanelles and extra ribs). The enlarged fontanelles are most likely due to calcipotrieneâ€™s effect upon calcium metabolism. The estimated maternal and fetal no-effect levels in the rat (108 mcg/m<span class="Sup">2</span>/day) and rabbit (48 mcg/m<span class="Sup">2</span>/day) studies are lower than the estimated maximum topical dose in man (approximately 460 mcg/m<span class="Sup">2</span>/day). Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Betamethasone dipropionate has been shown to be teratogenic in mice and rabbits when given by the subcutaneous route at doses of 156 mcg/kg/day (468 mcg/m<span class="Sup">2</span>/day) and 2.5 mcg/kg/day (30 mcg/m<span class="Sup">2</span>/day), respectively. Those dose levels are lower than the estimated maximum topical dose in man (5,948 mcg/m<span class="Sup">2</span>/day). The abnormalities observed included <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span>.</p>
<p>Pregnant women were excluded from the clinical trials conducted with Taclonex<span class="Sup">Â® </span>Ointment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_96fd4362-e2e7-41f0-80ce-fc1a3a665cb1"></a><a name="section-7.6"></a><p></p>
<h2>Nursing mothers:</h2>
<p class="First">Safety of the use of Taclonex<span class="Sup">Â®</span> Ointment during lactation has not been established.</p>
<p>Nursing women were excluded from the clinical trials conducted with Taclonex<span class="Sup">Â® </span>Ointment.</p>
<p>It is not known whether topically administered calcipotriene is excreted in human milk.</p>
<p>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk.</p>
<p>Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant.</p>
<p>Because many drugs are excreted in human milk, caution should be exercised when Taclonex<span class="Sup">Â®</span> Ointment is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9dcf02ad-838a-4c1b-b1fe-50dda7c1e30e"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric use:</h2>
<p class="First">Safety and effectiveness of Taclonex<span class="Sup">Â®</span> Ointment in pediatric patients have not been established. Because of a higher ratio of skin surface area to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_2b5516d5-adaa-4be9-b134-712f7db7a682"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric use:</h2>
<p class="First">Of the total number of subjects in clinical studies of Taclonex<span class="Sup">Â®</span> Ointment, approximately 14% were 65 years and older, while approximately 3% were 75 years and over.</p>
<p>No overall differences in safety or effectiveness of Taclonex<span class="Sup">Â®</span> Ointment were observed between these subjects and younger subjects. All other reported clinical experience has not identified any differences in response between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c9367e2b-dd2e-4960-9b84-3148dc0eb989"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p>The data described below reflect exposure to Taclonex<span class="Sup">Â® </span>Ointment in 2,448 patients, including 1,992 exposed for 4 weeks, and 289 exposed for 8 weeks. In the trials that included assessment of the effects of Taclonex<span class="Sup">Â®</span> Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Taclonex<span class="Sup">Â®</span> Ointment on calcium metabolism following treatment durations of longer than 4 weeks are not known (see <span class="Bold"><a href="#i4i_precautions_id_c0485ffa-39fb-4900-943b-7a204fbd92a4">PRECAUTIONS</a></span>). The effects of Taclonex<span class="Sup">Â® </span>Ointment on the HPA axis following treatment durations of longer than 4 weeks have not been adequately studied. Taclonex<span class="Sup">Â® </span>Ointment was studied primarily in placebo- and active-controlled trials (N = 1,176, and N = 1,272, respectively). The population was 15 - 97 years old, 61% males and 39% females, mostly white (97%) and had a baseline disease severity ranging from mild to very severe. Most patients received once daily application, and the median weekly dose was 24.5Â g.</p>
<p>The percentage of subjects reporting at least one adverse event was 27.1% in the Taclonex<span class="Sup">Â®</span> Ointment group, 33.0% in the calcipotriene group, 28.3% in the betamethasone group, and 33.4% in the vehicle group.</p>
<a name="id_3a342a88-9643-4c11-bc6e-3cc2625db85d"></a><table border="single" width="758">
<caption><span>Adverse Events Reported by â‰¥ 1% of Subjects by Preferred Term </span></caption>
<col width="40.6%">
<col width="15.2%">
<col width="14.5%">
<col width="15.2%">
<col width="14.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Taclonex<span class="Sup">Â®</span></span></p>
<p><span class="Bold">Ointment</span></p>
<span class="Bold">N = 2,448</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Calcipotriene</span></p>
<span class="Bold">N = 3,197</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Betamethasone</span></p>
<p><span class="Bold">dipropionate</span></p>
<span class="Bold">N = 1,164</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Vehicle</span></p>
<span class="Bold">N = 470</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Any Adverse Event</span></td>
<td class="Botrule Rrule" align="center" valign="top">663 (27.1)</td>
<td class="Botrule Rrule" align="center" valign="top">1055 (33.0)</td>
<td class="Botrule Rrule" align="center" valign="top">329 (28.3)</td>
<td class="Botrule Rrule" align="center" valign="top">157 (33.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Preferred Term</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold"># of subjects (%)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> scaly</p>
<p><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p>
<p><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p>
<p>Application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span></p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span></td>
<td class="Rrule" align="center" valign="top">
<p class="First">75 (3.1)</p>
<p>69 (2.8)</p>
<p>56 (2.3)</p>
<p>30 (1.2)</p>
<p>30 (1.2)</p>
<p>23 (0.9)</p>
<p>20 (0.8)Â </p>
<p>15 (0.6)</p>
<p>13 (0.5)Â </p>
<p>11 (0.4)</p>
<p>7 (0.3)</p>6 (0.2)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">183 (5.7)</p>
<p>75 (2.3)</p>
<p>77 (2.4)</p>
<p>47 (1.5)</p>
<p>40 (1.3)</p>
<p>34 (1.1)</p>
<p>19 (0.6)Â </p>
<p>54 (1.7)</p>
<p>24 (0.8)Â </p>
<p>60 (1.9)</p>
<p>12 (0.4)</p>30 (0.9)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">38 (3.3)</p>
<p>44 (3.8)</p>
<p>34 (2.9)</p>
<p>14 (1.2)</p>
<p>0 (0.0)</p>
<p>14 (1.2)</p>
<p>12 (1.0)Â </p>
<p>3 (0.3)</p>
<p>10 (0.9)Â </p>
<p>8 (0.7)</p>
<p>3 (0.3)</p>3 (0.3)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">43 (9.1)</p>
<p>12 (2.6)</p>
<p>9 (1.9)</p>
<p>5 (1.1)</p>
<p>1 (0.2)</p>
<p>6 (1.3)</p>
<p>3 (0.6)Â </p>
<p>5 (1.1)</p>
<p>6 (1.3)Â </p>
<p>5 (1.1)</p>
<p>5 (1.1)</p>6 (1.3)</td>
</tr>
</tbody>
</table>
<p>A lesional/perilesional adverse event was generally defined as an adverse event located â‰¤ 2 cm from the lesional border.</p>
<a name="id_28c402f9-d618-4f10-9a17-9687f3f5fb89"></a><table border="single" width="714">
<caption><span>Lesional/Perilesional Adverse Events Reported by â‰¥ 1% of Subjects </span></caption>
<col width="24.6%">
<col width="16.9%">
<col width="21.6%">
<col width="22.3%">
<col width="14.6%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Taclonex</span><span class="Sup">Â®</span></p>
<p><span class="Bold">Ointment</span></p>
<span class="Bold">N = 2,448</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Calcipotriene</span></p>
<span class="Bold">N = 3,197</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Betamethasone</span></p>
<p><span class="Bold">dipropionate</span></p>
<span class="Bold">N = 1,164</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Vehicle</span></p>
<span class="Bold">N = 470</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Any Adverse Event</span></td>
<td class="Botrule Rrule" align="center" valign="top">213 (8.7)</td>
<td class="Botrule Rrule" align="center" valign="top">419 (13.1)</td>
<td class="Botrule Rrule" align="center" valign="top">85 (7.3)</td>
<td class="Botrule Rrule" align="center" valign="top">76 (16.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Preferred Term</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold"># of subjects (%)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> scaly</p>
<p>Application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></p>
<p><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">Skin irritation</span></p><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span></td>
<td class="Rrule" align="center" valign="top">
<p class="First">69 (2.8)</p>
<p>29 (1.2)</p>
<p>12 (0.5)</p>
<p>9 (0.4)</p>
<p>9 (0.4)</p>6 (0.2)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">170 (5.3)</p>
<p>38 (1.2)</p>
<p>24 (0.8)</p>
<p>36 (1.1)</p>
<p>51 (1.6)</p>25 (0.8)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">31 (2.7)</p>
<p>0 (0.0)</p>
<p>10 (0.9)</p>
<p>2 (0.2)</p>
<p>8 (0.7)</p>3 (0.3)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">41 (8.7)</p>
<p>0 (0.0)</p>
<p>6 (1.3)</p>
<p>4 (0.9)</p>
<p>5 (1.1)</p>5 (1.1)</td>
</tr>
</tbody>
</table>
<p>For subjects who reported lesional/perilesional adverse events, the median time to onset was 7 days for Taclonex<span class="Sup">Â®</span> Ointment, 7 days for calcipotriene, 5 days for betamethasone dipropionate, and 3 days for vehicle.</p>
<p>Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>, and <span class="product-label-link" type="condition" conceptid="4041510" conceptname="Skin hypopigmented">skin hypopigmentation</span>. <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">Skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span> and <span class="product-label-link" type="condition" conceptid="4172432" conceptname="Hyperpigmentation of skin">skin hyperpigmentation</span> were reported infrequently (0.1%).</p>
<p>In a separate study, patients (N = 207) with at least moderate disease severity were given Taclonex<span class="Sup">Â®</span> Ointment intermittently on an â€œas neededâ€? basis for up to 52 weeks. The median use was 15.4 g per week.<span class="Bold"> The effects of Taclonex<span class="Sup">Â®</span> Ointment on calcium metabolism were not studied and the effects on the HPA axis were not adequately studied.</span> The following adverse reactions were reported by 1% or more of the patients: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (7.2%), <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (3.4%), <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span> (1.9%), <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span> (1.4%), <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> (1.4%), <span class="product-label-link" type="condition" conceptid="4048466" conceptname="Achromia of skin">skin depigmentation</span> (1.4%), <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span> (1.0%), <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (1.0%) and <span class="product-label-link" type="condition" conceptid="4031010" conceptname="Hand eczema">hand dermatitis</span> (1.0%). One case of a serious flare-up of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> was reported.</p>
<p>Development of <span class="product-label-link" type="condition" conceptid="4063434" conceptname="Pustular psoriasis">pustular psoriasis</span> has been reported as an adverse reaction during and following use of Taclonex<span class="Sup">Â®</span> Ointment. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a8c59eba-dd40-44ff-8de6-6cad5495481e"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied Taclonex<span class="Sup">Â®</span> Ointment can be absorbed in sufficient amounts to produce systemic effects. (See<span class="Bold"><a href="#i4i_precautions_id_c0485ffa-39fb-4900-943b-7a204fbd92a4"> PRECAUTIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_f042fb6b-401f-4ef1-939d-0cdee847f88f"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply an adequate layer of Taclonex<span class="Sup">Â®</span> Ointment to the affected area(s) once daily for up to 4 weeks. Taclonex<span class="Sup">Â®</span> Ointment should be rubbed in gently and completely. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended. Taclonex<span class="Sup">Â® </span>Ointment should not be applied to the face, axillae or groin.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_246595eb-7852-47e2-93fb-1addd8abe88c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Taclonex<span class="Sup">Â®</span> Ointment (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is available in 60 gram collapsible tubes (NDC 0430-3230-15) and 100 gram collapsible tubes (NDC 0430-3230-16).</p>
<p>Store Taclonex<span class="Sup">Â®</span> Ointment between 20 - 25Â° C (68 - 77Â° F); excursions permitted between 15 - 30Â° C (59 - 86Â° F).</p>
<p>Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_5c65916a-5028-45d1-b192-6f20dacbcde4"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">Patient Information</span></h1>
<p class="First"><span class="Bold">Taclonex<span class="Sup">Â®</span> Ointment</span></p>
<p><span class="Bold">(calcipotriene 0.005% and betamethasone dipropionate 0.064%)</span></p>
<p>Read the Patient Information that comes with Taclonex<span class="Sup">Â® </span>Ointment before you start using it and each time you use the ointment. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.</p>
<p><span class="Bold">What is Taclonex<span class="Sup">Â®</span> Ointment and what is it used for?</span></p>
<p>Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment is a prescription medicine called a topical (skin-use only). </p>
<p>Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment is used on the skin to treat <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> vulgaris in adults.</p>
<p>Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment contains </p>
<ul>
<li>calcipotriene hydrate, which is somewhat similar to vitamin D, <span class="Underline">but not the same as vitamin D,</span> and </li>
<li>betamethasone dipropionate, which is a strong (potent) corticosteroid.</li>
</ul>
<p>It is very important that you use Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment only as directed, in order to avoid serious side effects.</p>
<p>Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment is not recommended for use in children. Taclonex<span class="Bold"><span class="Sup">Â®</span></span> Ointment has not been studied in patients under the age of 18.</p>
<p><span class="Bold">Who should not use Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<p><span class="Bold">Do not use Taclonex<span class="Sup">Â®</span> Ointment if you: </span></p>
<ul>
<li><span class="Bold">have a calcium metabolism disorder</span></li>
<li>
<span class="Bold">have one of the following types of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>:</span><p class="First">oÂ Â Â <span class="product-label-link" type="condition" conceptid="4307927" conceptname="Erythrodermic psoriasis">erythrodermic psoriasis</span></p>
<p>oÂ Â Â exfoliative <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></p>
<p>oÂ Â Â <span class="product-label-link" type="condition" conceptid="4063434" conceptname="Pustular psoriasis">pustular psoriasis</span>   </p>
</li>
<li>
<span class="Bold">are allergic to anything in Taclonex<span class="Sup">Â®</span> Ointment</span>. See the end of this leaflet for a complete list of ingredients.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before using Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<p><span class="Bold">Tell your doctor about all of your health conditions, including if you:</span></p>
<ul>
<li>
<span class="Bold">have a <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span></span>. Your <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span> should be treated before starting Taclonex<span class="Sup">Â®</span> Ointment</li>
<li>
<span class="Bold">have thin-skin (<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>) at the site to be treated</span>. You should not use <br>Taclonex<span class="Sup">Â®</span> Ointment</li>
<li><span class="Bold">are getting phototherapy treatments for your <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></span></li>
<li>
<span class="Bold">are pregnant or planning to become pregnant</span>. It is not known if Taclonex<span class="Sup">Â®</span> Ointment can harm your unborn baby. You and your doctor will have to decide if Taclonex<span class="Sup">Â®</span> Ointment is right for you while pregnant</li>
<li>
<span class="Bold">are breastfeeding</span>. It is not known if Taclonex<span class="Sup">Â®</span> Ointment passes into your milk and if it can harm your baby</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription, and nonprescription medicines, vitamins and herbal supplements. </span>Taclonex<span class="Sup">Â®</span> Ointment and some other medicines can interact with each other. Especially tell your doctor if you use:</p>
<ul>
<li>other corticosteroid medicines</li>
<li>other medicines for your <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></li>
</ul>
<p><span class="Bold">How should I use Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<ul>
<li>
<span class="Bold">Use Taclonex<span class="Sup">Â®</span> Ointment exactly as directed by your doctor</span>. Do not use more than the recommended weekly amount of 100 grams of Taclonex<span class="Sup">Â®</span> Ointment. </li>
<li>
<span class="Bold">Do not use Taclonex<span class="Sup">Â®</span> Ointment on your face, under your arms or on your groin. Do not get any Taclonex<span class="Sup">Â®</span> Ointment in your eyes</span>. Wash your face or eyes right away if you get Taclonex<span class="Sup">Â®</span> Ointment on them.</li>
</ul>
<p><span class="Bold">Using Taclonex<span class="Sup">Â®</span> Ointment:</span></p>
<ul>
<li>Remove the cap and check that the aluminum seal covers the tube, before the first use. To break the seal, turn the cap over and push through the seal. </li>
<li>Apply Taclonex<span class="Sup">Â®</span> Ointment once a day to the areas of your skin affected by <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. Gently rub Taclonex<span class="Sup">Â®</span> Ointment into your affected skin areas. </li>
<li>Do not bandage or tightly cover or wrap the treated skin area. Wear your usual clothes. </li>
<li>Only use Taclonex<span class="Sup">Â®</span> Ointment as directed by your doctor. Taclonex<span class="Sup">Â®</span> Ointment is recommended for up to 4 weeks of treatment. Do not use Taclonex<span class="Sup">Â®</span> Ointment for more than 4 weeks unless prescribed by your doctor. </li>
<li>If you forget to use your Taclonex<span class="Sup">Â®</span> Ointment, use it as soon as you remember. Then go on as before. </li>
<li>Wash your hands well after using Taclonex<span class="Sup">Â®</span> Ointment.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<p>The most common side effects are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </li>
<li>skin burning</li>
</ul>
<p>Â Other less common side effects with Taclonex<span class="Sup">Â®</span> Ointment include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the skin </li>
<li>inflamed hair pores (<span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>) </li>
<li><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span> </li>
<li>change of skin color (at the site of application) </li>
<li>thinning of the skin (<span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>)</li>
<li>swollen fine blood vessels (this makes your skin appear red at the site of  application)</li>
</ul>
<p><span class="Bold">Taclonex<span class="Sup">Â®</span> Ointment may cause serious side effects if you use too much or use it for too long</span>. Taclonex<span class="Sup">Â®</span> Ointment can pass through your skin. Serious side effects may include:</p>
<ul>
<li><span class="Bold">too much calcium in your blood</span></li>
<li><span class="Bold">adrenal gland problems<br></span></li>
</ul>
<p>Your doctor may do special blood and urine tests to check your calcium levels and adrenal gland function while you are using Taclonex<span class="Sup">Â®</span> Ointment.</p>
<p>Call your doctor about any side effect that bothers you or that does not go away.</p>
<p>These are not all of the side effects with Taclonex<span class="Sup">Â®</span> Ointment. Ask your doctor or pharmacist for more information.</p>
<p><span class="Bold">How should I store Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<ul>
<li>Taclonex<span class="Sup">Â®</span> Ointment should be stored between 68 - 77Â° F (20 - 25Â° C); excursions permitted between 59 - 86Â° F (15 - 30Â° C). Make sure the cap on the tube is tightly closed. </li>
<li>Taclonex<span class="Sup">Â®</span> Ointment has an expiry date marked on the tube. Do not use the ointment after this date. </li>
<li>
<span class="Bold">Keep Taclonex<span class="Sup">Â®</span> Ointment out of the reach of children and pets</span>.</li>
</ul>
<p><span class="Bold">General information about Taclonex<span class="Sup">Â®</span> Ointment </span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Taclonex<span class="Sup">Â®</span> Ointment for a condition for which it was not prescribed. Do not give ointment to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about Taclonex<span class="Sup">Â®</span> Ointment. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Taclonex<span class="Sup">Â®</span> Ointment that is written for health professionals. </p>
<p>Additional consumer information is available at (800) 521-8813.</p>
<p><span class="Bold">What are the ingredients in Taclonex<span class="Sup">Â®</span> Ointment?</span></p>
<p>Active ingredients: calcipotriene hydrate, betamethasone dipropionate</p>
<p>Inactive ingredients: mineral oil, PPG-15 stearyl ether, dl-alpha tocopherol, white petrolatum. </p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="LEO Laboratories Ltd. logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-03.jpg"></div>
<p><img alt="LEO Laboratories Ltd. Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-04.jpg"></p>
<p>Manufactured by:<br>LEO Laboratories Ltd. (LEO Pharma)<br>Dublin, Ireland</p>
<p>Â </p>
<div class="Figure"><img alt="Warner Chilcott (US) logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-05.jpg"></div>
<p>Â </p>
<p>Marketed by:<br>Warner Chilcott (US), LLC <br>Rockaway, NJ 07866 USA<br>1-800-521-8813</p>
<p>U.S. Patent Nos.: RE39,706 E and 6,753,013.</p>
<p>3230G025<br>3230G125<br>022608-05                                                                </p>
<p>Revised July 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_03ec8278-5aff-4c77-abf8-1d4b02e67c2b"></a><a name="section-13"></a><p></p>
<h1>PRINCIPALÂ DISPLAYÂ PANELÂ -Â CARTONÂ LABELÂ 100Â g</h1>
<div class="Figure"><img alt="Taclonex Ointment Carton Label 100 g" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=afa386a0-1345-46a7-a06f-40f54ee51693&amp;name=3da6d640-26a4-40cf-9f5d-9eaac588d6ff-06.jpg"></div>
<p class="First">NDCÂ 0430-3230-16<br><span class="Bold">TACLONEX<span class="Sup">Â®</span></span><span class="Bold">(</span>calcipotriene <span class="Bold">0.005% and </span>betamethasone dipropionate<span class="Bold"> 0.064%)</span><span class="Bold">Â Ointment</span></p>
<p><span class="Bold">RxÂ only</span></p>
<p><span class="Bold">ForÂ TopicalÂ UseÂ Only</span></p>
<p><span class="Bold">NetÂ Wt.Â 100Â g</span></p>
<p>EachÂ gramÂ containsÂ 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone)Â inÂ anÂ ointmentÂ baseÂ ofÂ mineral oil, PPG-15 stearyl ether, dl-alpha tocopherolÂ and white petrolatum.</p>
<p>StoreÂ Taclonex<span class="Sup">Â®</span> OintmentÂ between 20 - 25Â° CÂ (68 - 77Â° F); excursions permitted between 15 - 30Â° CÂ (59 - 86Â° F).</p>
<p>KeepÂ outÂ ofÂ reachÂ ofÂ children.</p>
<p>UsualÂ Dosage:Â ApplyÂ onceÂ daily,Â orÂ asÂ directedÂ byÂ physician.Â SeeÂ InsertÂ forÂ completeÂ information.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TACLONEXÂ 		
					</strong><br><span class="contentTableReg">calcipotriene and betamethasone dipropionate ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-3230</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCIPOTRIENE</strong> (CALCIPOTRIENE) </td>
<td class="formItem">CALCIPOTRIENE</td>
<td class="formItem">50Â ug Â inÂ 1Â g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BETAMETHASONE DIPROPIONATE</strong> (BETAMETHASONE DIPROPIONATE) </td>
<td class="formItem">BETAMETHASONE DIPROPIONATE</td>
<td class="formItem">0.643Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALPHA-TOCOPHEROL, DL-</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-3230-15</td>
<td class="formItem">100  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-3230-16</td>
<td class="formItem">50  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0430-3230-95</td>
<td class="formItem">25  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">3 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021852</td>
<td class="formItem">06/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), LLC
							(957203177)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LEO Laboratories Ltd. (LEO Pharma)</td>
<td class="formItem"></td>
<td class="formItem">306218106</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3da6d640-26a4-40cf-9f5d-9eaac588d6ff</div>
<div>Set id: afa386a0-1345-46a7-a06f-40f54ee51693</div>
<div>Version: 3</div>
<div>Effective Time: 20091210</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), LLC</div></p>
</body></html>
